New hope for kids with Drug-Resistant TB: pretomanid dose study completed
NCT ID NCT05586230
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a single dose of the drug pretomanid in 32 children with rifampicin-resistant tuberculosis (TB). The goal was to see how the drug moves through the body and whether it is safe when added to their regular TB treatment. The children were monitored for 48 hours after taking the drug. This is an early step toward finding better treatments for children with hard-to-treat TB.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pretomanid
What this could lead to
If successful, this could help determine the right dose of pretomanid for children with drug-resistant TB, potentially leading to better treatment options.
What could go wrong
This is a very early phase 1 study with only 32 children and a single dose. It focuses on safety and drug levels, not on curing the disease. More research is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 31441, BJMC CRS
Pune, India
-
Site 31790, Desmond Tutu TB Centre (DTTC) CRS
Cape Town, South Africa
-
Site 31929, Sizwe CRS
Johannesburg, South Africa
-
Site 31976, PHRU Matlosana CRS
Klerksdorp, North West, 2574, South Africa
-
Site 5071, Instituto de Puericultura e Pediatria Martagao Gesteira CRS
Rio de Janeiro, Brazil
-
Site 5115, Siriraj Hospital, Mahidol University NICHD CRS
Bangkok Noi, Thailand